Previous close | 4.5500 |
Open | 4.8000 |
Bid | 1.6500 |
Ask | 2.5000 |
Strike | 150.00 |
Expiry date | 2025-01-17 |
Day's range | 4.5500 - 4.8000 |
Contract range | N/A |
Volume | |
Open interest | 114 |
It's been a good week for Biogen Inc. ( NASDAQ:BIIB ) shareholders, because the company has just released its latest...
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.